
FDA Removes Partial Clinical Hold on Gilead’s MDS and AML Magrolimab Studies By Investing.com
© Reuters FDA Removes Partial Clinical Hold on Gilead’s (GILD) MDS and AML Magrolimab Studies Gilead Sciences, Inc. (Nasdaq: NASDAQ:) announced that the U.S. Food and Drug Administration (FDA) decided to remove its partial clinical […]